Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers.

Psychopharmacology bulletin - 2 Jan 2026

Skryabin Valentin, Masyakin Anton, Pozdniakov Sergei, Shatokhin Igor, Sokolova Svetlana, Ivanchenko Valentina, Makartseva Polina

Abstract excerpt

Background: Acute alcoholic hallucinosis (ICD-10 F10.52) necessitates urgent antipsychotic treatment but carries high risks of adverse drug reactions (ADRs). While pharmacogenetic clinical decision support systems (CDSS) show promise, their utility is limited by static genotyping and incomplete biomarker integration. Purpose: This study aimed to develop and validate a multi-omics framework integrating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP3A

Share to MicroRNAs

Share to Pharmacogenomic Testing

Share to Phenotype

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 41532000
DOI: 10.64719/pb.15425
PMCID: PMC12795285

Genes

CYP3A4
F10

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers.PMID 41532000Read ↗

Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers.Semantic proximity Read ↗

GENETIC VARIANTS IN ANTIPSYCHOTIC METABOLISM: POLYMORPHISM PROFILES IN KAZAKH COHORT WITH PARANOID SCHIZOPHRENIA.Semantic proximity Read ↗

Interindividual Variability in Olanzapine Steady-State Concentrations in Chinese: Exploring Single Nucleotide Polymorphisms of Metabolic EnzymesSemantic proximity Read ↗

Pharmacogenomics in practice: a case report of personalized inpatient psychiatric care.Semantic proximity Read ↗

Relationship of CYP3A4*1B Single Nucleotide Polymorphism to the Efficiency and Safety Profiles of Haloperidol in Patients Enduring Acute Alcoholic Hallucinosis.Semantic proximity Read ↗

Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.Semantic proximity Read ↗

Metabolic, genetic, and pharmacokinetic parameters for the prediction of olanzapine efficacy.Semantic proximity Read ↗

Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomicsSemantic proximity Read ↗

Relationship of the 1846G > A Polymorphism of the CYP2D6 Gene to the Equilibrium Concentration Levels of Haloperidol in Patients with Acute Alcoholic Hallucinosis.Semantic proximity Read ↗

Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses.Semantic proximity Read ↗

The pharmacogenetics of treatment with olanzapineSemantic proximity Read ↗

COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.